Antibody Solutions will be attending Keystone Symposia's Molecular Approaches 2019, to be held February 10-15 in Keystone, CO.
Vaccines address public health issues ranging from pandemic outbreaks to childhood disease. Despite this diversity, molecular approaches are beginning to find broad application. This Keystone Symposia conference seeks to bring together antibody aficionados, B cell immunologists, structural biologists, and vaccine developers from government, academia, biotechnology, and major pharmaceutical companies to review the utility of structure-based vaccine design and antibody-based immune monitoring, and in doing so hope to transform standard approaches of vaccine development. This meeting aims (1) to provide examples of the ”antibody-to-vaccine” paradigm for RSV, CMV and other pathogens that have resisted standard vaccinology; (2) to describe procedures whereby B cells can be taught to make the right antibodies; (3) to describe molecular approaches for vaccine improvement; and (4) to discuss how molecular approaches can be used to speed development (as may be needed, for example, in the case of pandemics) and to reduce developmental and regulatory costs (for vaccines in general and in particular to enable provision to the developing world). Overall, we seek to integrate molecular approaches for vaccine development and read-out with other transformative advances, including mRNA delivery, next-generation sequencing of B cell transcripts, and control of B cell-T cell interactions. This conference will be held jointly with a Keystone Symposia conference on B Cell-T Cell Interactions and several shared sessions will highlight synergistic areas of research between these communities.
For more information about this conference, please go to: http://www.keystonesymposia.org/index.cfm?e=web.Meeting.Program&meetingid=1625
If you are planning on attending this year's conference and would like to meet with a member of our team while at the show, we'd love to connect with you! You can request to schedule a meeting with one of our antibody research experts here.